secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001493152-26-007750
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals' MGX-0024 zero respiratory mortality in 29,000-bird trial; 60% H5N1 mortality cut
--------------------------------------------------------------------------------

- Three commercial field trials in India (~29,000 broilers) with MGX-0024 drinking water showed zero respiratory-related mortality vs. historical ~50%.
- Controlled H5N1 challenge (ICAR-NIHSAD): 48-hr pre-treatment reduced mortality 60% (2/7 vs 5/7 deaths) and extended mean time to death to 10.71 days.
- Surviving birds in H5N1 study were seronegative for H5 antibodies at day 14, suggesting early interference with infection establishment.
- MGX-0024 is a GRAS-classified polyphenol/zinc formulation forming respiratory barrier; protected by US Patent 11,517,523 and international patents.
- Company scaling production, pursuing regulatory discussions in US, UK, Australia, and targets commercial rollout in select markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226007750/0001493152-26-007750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226007750/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer